Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Uncommon EGFR Mutations”

35 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 35 results

Testing effectiveness (Phase 2)UnknownNCT05277701
What this trial is testing

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations

Who this might be right for
NSCLC
Yonsei University 36
Testing effectiveness (Phase 2)Looking for participantsNCT07117890
What this trial is testing

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Who this might be right for
Non Small Cell Lung Cancer
Fudan University 34
Testing effectiveness (Phase 2)Study completedNCT03434418
What this trial is testing

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
Duke University 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT04504071
What this trial is testing

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung Cancer
Shanghai Chest Hospital 30
Testing effectiveness (Phase 2)UnknownNCT04553887
What this trial is testing

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 53
Not applicableStudy completedNCT01215474
What this trial is testing

Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC

Who this might be right for
Mutations in Exons 18 to 21
Provitro GmbH 500
Testing effectiveness (Phase 2)Looking for participantsNCT05168566
What this trial is testing

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Teligene US 99
Not applicableTemporarily pausedNCT05421936
What this trial is testing

Osimertinib for NSCLC With Uncommon EGFR Mutations

Who this might be right for
Carcinoma, Non-Small-Cell LungGenes, erbB-1
Sheba Medical Center 100
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Large-scale testing (Phase 3)Active Not RecruitingNCT07128199
What this trial is testing

Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Who this might be right for
Lung CancerAdjuvantPost-surgical+5 more
Taiho Oncology, Inc. 360
Large-scale testing (Phase 3)UnknownNCT04951648
What this trial is testing

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 220
Testing effectiveness (Phase 2)Study completedNCT04790409
What this trial is testing

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Who this might be right for
Lung Cancer
Zhejiang Cancer Hospital 21
Testing effectiveness (Phase 2)Ended earlyNCT05215951
What this trial is testing

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 4
Testing effectiveness (Phase 2)UnknownNCT06029816
What this trial is testing

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations

Who this might be right for
NSCLC
Convalife (Shanghai) Co., Ltd. 42
Large-scale testing (Phase 3)Looking for participantsNCT07010419
What this trial is testing

Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

Who this might be right for
NSCLCAdjuvant Treatment
Allist Pharmaceuticals, Inc. 338
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 675
Not applicableUnknownNCT01775943
What this trial is testing

Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Who this might be right for
Lung Neoplasms
Ulsan University Hospital 90
Testing effectiveness (Phase 2)UnknownNCT05548348
What this trial is testing

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Who this might be right for
Non-small Cell Lung CancerEGFR G719XEGFR L861Q+1 more
Chongqing University Cancer Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06517953
What this trial is testing

Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more
Sun Yat-sen University 23
Testing effectiveness (Phase 2)Looking for participantsNCT06010329
What this trial is testing

Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Teligene US 66
Next Page
480